Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
05 Sep 2024
Historique:
received: 14 05 2024
medline: 5 9 2024
pubmed: 5 9 2024
entrez: 5 9 2024
Statut: aheadofprint

Résumé

Not available.

Identifiants

pubmed: 39234873
doi: 10.3324/haematol.2024.285837
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Christina Peters (C)

St. Anna Children's Hospital, St. Anna Children's Cancer Research Institute, University Vienna, Vienna.

Angela Bruno (A)

Amgen Italia, Milan.

Carmelo Rizzari (C)

MBBM Foundation, University of Milano-Bicocca, Monza.

Alessandra Brescianini (A)

Amgen (Europe) GmbH, Rotkreuz.

Arend Von Stackelberg (A)

Charité Universitaetsmedizin CVK Berlin, Berlin.

Christin Linderkamp (C)

Medizinische Hochschule Hannover, Hannover.

Yi Zeng (Y)

Amgen Inc., Thousand Oaks, CA.

Gerhard Zugmaier (G)

Amgen Research (Munich) GmbH, Munich. gerhardz@amgen.com.

Franco Locatelli (F)

IRCCS Ospedale Pediatrico Bambino Gesù and Catholic University of the Sacred Heart, Rome.

Classifications MeSH